Biomira shows statistically significant improvement in survival in breast cancer trial with THERATOPE cancer vaccine program.SAN DIEGO--(BUSINESS WIRE)--Dec. 7, 1995-- Dr. Grant MacLean, Medical Oncologist medical oncologist Oncology An oncologist who diagnoses and treats cancer with chemotherapy, hormones, biologicals, or immunologic agents; the MO becomes a cancer Pt's de facto primary care giver, and coordinates treatment provided by other specialists. and principal investigator Noun 1. principal investigator - the scientist in charge of an experiment or research project PI scientist - a person with advanced knowledge of one or more sciences for Biomira's clinical study at the Cross Cancer Institute in Edmonton, Alberta today presented results of Biomira's Phase II clinical trials of THERATOPE (R) therapeutic vaccine therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. , in patients with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer. The meeting "Novel Vaccine Strategies: Immunotherapeutic Strategies for Cancer" Conference was held in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. . THERATOPE (R) therapeutic vaccine is a non-toxic therapy designed to stimulate the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. of cancer patients to respond against the cancer. The study was conducted over a 2 1/2 year period at the Cross Cancer Institute in Edmonton and Guy's Hospital in London. Among 48 women in a randomized clinical trial randomized clinical trial, n a clinical study where volunteer participants with comparable characteristics are randomly assigned to different test groups to compare the efficacy of therapies. , Dr. MacLean reported that 24 who received THERATOPE (R) vaccine in its standard investigational program had a statistically significant increase in survival over 24 women in the other study group who did not receive the standard immunomodulation prior to THERATOPE (R) vaccine treatment. The women on the standard THERATOPE (R) therapeutic vaccine program have a projected median survival of 19.7 months versus 12.6 months for the other study group, with statistical significant at p=0.018. In addition to increased survival, the women on the standard THERATOPE (R) vaccine program had statistically significant higher levels of antibodies against a specific molecule, Sialyl-Tn (STn), found on the surface of breast cancer cells, than was observed with those who received the alternate THERATOPE (R) program. Since receiving the analysis of the data, Biomira has been consulting with clinical investigators and scientists about these results and will be contacting regulatory officials in the U.S., Canada and Europe to discuss their recommendations for the next steps to take THERATOPE (R) therapeutic vaccine to commercialization for women who suffer from metastatic breast cancer. Biomira is a biotechnology company specializing in developing vaccine and cellular therapies for CANCER MANAGEMENT . . . from discovery to recovery (TM). The company also develops novel diagnostic products to aid in the detection of recurrent cancer recurrent cancer Oncology A cancer that reappears in a site where it was eradicated or disappeared. Cf Remission, Residual cancer. through the blood tests or imaging agents, as well as a diagnostic product candidate designed to identify a patient's immune system deficiencies and assess the potential of the patient to respond to immune-based therapies. CONTACT: Jane Jack Biomira Inc. 403/490-2812 or For December 7 & 8, 1995 Only! Jane Jack c/o San Diego Hilton 619/276-4010 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion